The Bcl-2/Bcl-X L/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 10, Issue 12, 2011, Pages 2340-2349

  Chen, Jun ^a   Jin, Sha ^a   Abraham, Vivek ^a   Huang, Xiaoli ^a   Liu, Bernard ^b   Mitten, Michael J ^a   Nimmer, Paul ^a   Lin, Xiaoyu ^a   Smith, Morey ^a   Shen, Yu ^a   Shoemaker, Alexander R ^a   Tahir, Stephen K ^a   Zhang, Haichao ^a   Ackler, Scott L ^a   Rosenberg, Saul H ^a   Maecker, Heather ^c   Sampath, Deepak ^c   Leverson, Joel D ^a   Tse, Chris ^a   Elmore, Steven W ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; IMATINIB; LAPATINIB; NAVITOCLAX; PEMETREXED; PROTEIN BCL 2; PROTEIN MCL 1; RAPAMYCIN; ROSCOVITINE; SMALL INTERFERING RNA; SORAFENIB; TEMOZOLOMIDE; VINCRISTINE; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; XENOGRAFT;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; DRUG SYNERGISM; FEMALE; HCT116 CELLS; HEP G2 CELLS; HUMANS; K562 CELLS; MALE; MICE; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83355166908     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0415     Document Type: Article

References (33)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70. (Pubitemid 30046295)
2. Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003;13:115-23. (Pubitemid 36315930)
3. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19. (Pubitemid 38167313)
4. Gelinas C, White E. BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 2005;19: 1263-8. (Pubitemid 41003016)
5. Tan TT, White E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv Exp Med Biol 2008;615:81-104.
6. Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 2000;53:15-8. (Pubitemid 30075069)
7. Castilla C, Congregado B, Chinchon D, Torrubia FJ, Japon MA, Saez C. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006;147:4960-7. (Pubitemid 44402203)
8. Zhang Y, Fujita N, Tsuruo T. p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int J Cancer 1999;83:790-7.
9. Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, et al. BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm 2002;17:647-56. (Pubitemid 36025946)
10. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993;192:30-6. (Pubitemid 23205264)
11. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4. (Pubitemid 23006303)
12. Storey S. Targeting apoptosis: selected anticancer strategies. Nat Rev Drug Discov 2008;7:971-2.
13. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
14. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 2008;14: 3268-77.
15. Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther 2008;7:3265-74.
16. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, et al. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 2011;17:1394-404.
17. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
18. Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP, Korsmeyer SJ. Bcl-2 gene family and the regulation of programmed cell death. Cold Spring Harb Symp Quant Biol 1994;59:387-93.
19. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005;65:2513-31. (Pubitemid 41697318)
20. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67: 1176-83.
21. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene 2007;26:3972-9. (Pubitemid 46884293)
22. Yokoyama H, Ikehara Y, Kodera Y, Ikehara S, Yatabe Y, Mochizuki Y, et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006;95:1504-13. (Pubitemid 44863353)
23. Yamamoto T, Kamata N, Kawano H, Shimizu S, Kuroki T, Toyoshima K, et al. High incidence of amplification of the epidermal growth factor receptor gene in human squamous carcinoma cell lines. Cancer Res 1986;46:414-6. (Pubitemid 16189082)
24. Gillies SD, Azria D, Larbouret C, Pelegrin A, inventors; L'Instut National de la Sante et de la Recherche Medicale, assignee. Combination therapy using anti-EGFR and anti-HER2 antibodies. United States patent US 20090214541. 2009.
25. Choi JH, Choi KC, Auersperg N, Leung PC. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2004;89:5508-16. (Pubitemid 39518434)
26. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11. (Pubitemid 39209661)
27. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
28. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681-9; discussion 1690.
29. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:2934-49. (Pubitemid 38638854)
30. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorick R, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50: 1181-9. (Pubitemid 351555542)
31. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001;7:1079-86. (Pubitemid 32708748)
32. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10: 375-88. (Pubitemid 44693472)
33. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-91. (Pubitemid 46192219)